A adenoid cystic carcinoma that involves the lymph node.
Comprehensive, easy-to-understand information about this condition
How we create this content →The limited documentation surrounding lymph node adenoid cystic carcinoma can be attributed to its rarity, which affects fewer than 5,000 individuals in the U.S. This rarity leads to a lack of systematic clinical studies and comprehensive data collection, making it difficult to establish a clearer understanding of the disease's characteristics and treatment options.
To navigate your care for lymph node adenoid cystic carcinoma, consider seeking a specialist in oncology with experience in rare cancers. Engaging with a genetic counselor may also be beneficial, even though no genetic basis has been established. For additional support, you can explore resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov. While there are no patient organizations currently identified for this specific condition, connecting with broader cancer support networks may provide helpful resources.
Currently, there are several orphan drugs designated for lymph node adenoid cystic carcinoma, including a potent and selective inhibitor of Gamma Secretase-mediated NOTCH signaling, a small molecule mRNA degrader of MYB, and others like dovitinib and Rivoceranib. However, there are no active clinical trials available. For more information on ongoing research, you can search ClinicalTrials.gov for updates on related studies.
Actionable guidance for navigating care for lymph node adenoid cystic carcinoma
To navigate your care for lymph node adenoid cystic carcinoma, consider seeking a specialist in oncology with experience in rare cancers. Engaging with a genetic counselor may also be beneficial, even though no genetic basis has been established. For additional support, you can explore resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov. While there are no patient organizations currently identified for this specific condition, connecting with broader cancer support networks may provide helpful resources.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The limited documentation surrounding lymph node adenoid cystic carcinoma can be attributed to its rarity, which affects fewer than 5,000 individuals in the U.S. This rarity leads to a lack of systematic clinical studies and comprehensive data collection, making it difficult to establish a clearer understanding of the disease's characteristics and treatment options.
To navigate your care for lymph node adenoid cystic carcinoma, consider seeking a specialist in oncology with experience in rare cancers. Engaging with a genetic counselor may also be beneficial, even though no genetic basis has been established. For additional support, you can explore resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov. While there are no patient organizations currently identified for this specific condition, connecting with broader cancer support networks may provide helpful resources.
Currently, there are several orphan drugs designated for lymph node adenoid cystic carcinoma, including a potent and selective inhibitor of Gamma Secretase-mediated NOTCH signaling, a small molecule mRNA degrader of MYB, and others like dovitinib and Rivoceranib. However, there are no active clinical trials available. For more information on ongoing research, you can search ClinicalTrials.gov for updates on related studies.
Actionable guidance for navigating care for lymph node adenoid cystic carcinoma
To navigate your care for lymph node adenoid cystic carcinoma, consider seeking a specialist in oncology with experience in rare cancers. Engaging with a genetic counselor may also be beneficial, even though no genetic basis has been established. For additional support, you can explore resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov. While there are no patient organizations currently identified for this specific condition, connecting with broader cancer support networks may provide helpful resources.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The limited documentation surrounding lymph node adenoid cystic carcinoma can be attributed to its rarity, which affects fewer than 5,000 individuals in the U.S. This rarity leads to a lack of systematic clinical studies and comprehensive data collection, making it difficult to establish a clearer understanding of the disease's characteristics and treatment options.
To navigate your care for lymph node adenoid cystic carcinoma, consider seeking a specialist in oncology with experience in rare cancers. Engaging with a genetic counselor may also be beneficial, even though no genetic basis has been established. For additional support, you can explore resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov. While there are no patient organizations currently identified for this specific condition, connecting with broader cancer support networks may provide helpful resources.
Currently, there are several orphan drugs designated for lymph node adenoid cystic carcinoma, including a potent and selective inhibitor of Gamma Secretase-mediated NOTCH signaling, a small molecule mRNA degrader of MYB, and others like dovitinib and Rivoceranib. However, there are no active clinical trials available. For more information on ongoing research, you can search ClinicalTrials.gov for updates on related studies.
Actionable guidance for navigating care for lymph node adenoid cystic carcinoma
To navigate your care for lymph node adenoid cystic carcinoma, consider seeking a specialist in oncology with experience in rare cancers. Engaging with a genetic counselor may also be beneficial, even though no genetic basis has been established. For additional support, you can explore resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov. While there are no patient organizations currently identified for this specific condition, connecting with broader cancer support networks may provide helpful resources.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Consider asking your healthcare providers these condition-specific questions
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.